Associations between anticholinergic medication exposure and adverse health outcomes in older people with frailty: A systematic review and meta-analysis
Mehdizadeh, D. Hale, M. Todd, O. Marques, I. Petty, Duncan R. Alldred, D.P. Johnson, O.
Mehdizadeh, D.
Hale, M.
Todd, O.
Marques, I.
Petty, Duncan R.
Alldred, D.P.
Johnson, O.
Publication Date
2021-06-23
End of Embargo
Supervisor
Rights
© The Author(s) 2021. This article is licensed under a Creative Commons Attribution-
NonCommercial 4.0 International License, which permits any
non-commercial use, sharing, adaptation, distribution and reproduction
in any medium or format, as long as you give appropriate credit to the
original author(s) and the source, provide a link to the Creative Commons
licence, and indicate if changes were made. The images or other
third party material in this article are included in the article’s Creative
Commons licence, unless indicated otherwise in a credit line to the
material. If material is not included in the article’s Creative Commons
licence and your intended use is not permitted by statutory regulation
or exceeds the permitted use, you will need to obtain permission
directly from the copyright holder. To view a copy of this licence, visit
http:// creat iveco mmons. org/ licen ses/ by- nc/4. 0/.
Peer-Reviewed
Yes
Open Access status
openAccess
Accepted for publication
2021-03-10
Institution
Department
Awarded
Embargo end date
Collections
Additional title
Abstract
There are robust associations between use of anticholinergic medicines and adverse effects in older people. However, the nature of these associations for older people living with frailty is yet to be established.
The aims were to identify and investigate associations between anticholinergics and adverse outcomes in older people living with frailty and to investigate whether exposure is associated with greater risks according to frailty status.
MEDLINE, CINAHL, EMBASE, Cochrane Database of Systematic Reviews, Web of Science and PsycINFO were searched to 1 August 2019. Observational studies reporting associations between anticholinergics and outcomes in older adults (average age ≥ 65 years) that reported frailty using validated measures were included. Primary outcomes were physical impairment, cognitive dysfunction, and change in frailty status. Risk of bias was evaluated using the Cochrane Risk of Bias In Non-randomised Studies of Interventions (ROBINS-I) tool. Meta-analysis was undertaken where appropriate.
Thirteen studies (21,516 participants) were included (ten community, one residential aged-care facility and two hospital studies). Observed associations included reduced ability for chair standing, slower gait speeds, poorer physical performance, increased risk of falls and mortality. Conflicting results were reported for grip strength, timed up and go test, cognition and activities of daily living. No associations were observed for transitions between frailty states, psychological wellbeing or benzodiazepine-related adverse reactions. There was no clear evidence of differences in risks according to frailty status.
Anticholinergics are associated with adverse outcomes in older people living with frailty; however, the literature has significant methodological limitations. There is insufficient evidence to suggest greater risks based on frailty, and there is an urgent need to evaluate this further in well-designed studies stratifying by frailty.
Version
Published version
Citation
Mehdizadeh D, Hale M, Todd O et al (2021) Associations between anticholinergic medication exposure and adverse health outcomes in older people with frailty: A systematic review and meta-analysis. Drugs - Real World Outcomes. 8: 431-458.
Link to publisher’s version
Link to published version
Link to Version of Record
Type
Article